Market capitalization | $33.92m |
Enterprise Value | $101.74m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 0.05 |
P/S ratio (TTM) P/S ratio | 0.02 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -3.29% |
Revenue (TTM) Revenue | $2.04b |
EBIT (operating result TTM) EBIT | $-38.66m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast 111, Inc. Sponsored ADR Class A:
1 Analyst has issued a forecast 111, Inc. Sponsored ADR Class A:
Jun '24 |
+/-
%
|
||
Revenue | 2,038 2,038 |
3%
3%
|
|
Gross Profit | 114 114 |
12%
12%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -39 -39 |
6%
6%
|
Net Profit | -46 -46 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment engages in the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.
Head office | Cayman Islands |
CEO | Jun Liu |
Employees | 1,520 |
Founded | 2013 |
Website | www.111.com.cn |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.